Spago Nanomedical AB (OSTO:SPAGO) LT-Debt-to-Total-Asset : 0.00 (As of Mar. 2024)

View and export this data going back to 2012. Start your Free Trial

What is Spago Nanomedical AB LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Spago Nanomedical AB's long-term debt to total assests ratio for the quarter that ended in Mar. 2024 was 0.00.

Spago Nanomedical AB's long-term debt to total assets ratio stayed the same from Mar. 2023 (0.00) to Mar. 2024 (0.00).

Spago Nanomedical AB LT-Debt-to-Total-Asset Historical Data

The historical data trend for Spago Nanomedical AB's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spago Nanomedical AB LT-Debt-to-Total-Asset Chart

Spago Nanomedical AB Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

Spago Nanomedical AB Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															-	-	-	-	-

Spago Nanomedical AB LT-Debt-to-Total-Asset Calculation

Spago Nanomedical AB's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Dec. 2023 is calculated as

LT Debt to Total Assets (A: Dec. 2023 )	=	Long-Term Debt & Capital Lease Obligation (A: Dec. 2023 )	/	Total Assets (A: Dec. 2023 )
	=	0	/	52.985
	=	0.00

Spago Nanomedical AB's Long-Term Debt to Total Asset Ratio for the quarter that ended in Mar. 2024 is calculated as

LT Debt to Total Assets (Q: Mar. 2024 )	=	Long-Term Debt & Capital Lease Obligation (Q: Mar. 2024 )	/	Total Assets (Q: Mar. 2024 )
	=	0	/	41.468
	=	0.00

Spago Nanomedical AB (OSTO:SPAGO) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Spago Nanomedical AB LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of Spago Nanomedical AB's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Spago Nanomedical AB (OSTO:SPAGO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spago Nanomedical AB (OSTO:SPAGO) » Definitions » LT-Debt-to-Total-Asset

Comparable Companies

Traded in Other Exchanges

7UX:Germany

Address

Scheelevagen 22, Lund, SWE, SE-223 63

Website

https://www.spagonanomedical.se

Spago Nanomedical AB is a nanomedicine company in the field of cancer diagnosis and treatment. The company's product includes SpagoPix and Tumorad. The SpagoPix product aims to improve cancer diagnosis with magnetic resonance imaging through previous detection of tumors and metastases. The Tumorad products focuses on the development of a completely new form of radionuclide therapy for tumor selective radiation therapy of cancer. The company development projects are based on a platform of polymeric materials with varoious properties for precise diagnosis and treatment of life threatening and debilitating diseases.

Spago Nanomedical AB (OSTO:SPAGO) Headlines

No Headlines